Who Paid My Doc
Maged Hosny
Rheumatology Dover, DE Medical Doctor
NPI 1326003351 CMS profile 105005
260 Beiser Blvd Ste 201, Dover, DE 19904
General payments
$1,208
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Maged Hosny of Dover, DE is reported in the CMS Open Payments database as having received $1,208 across 66 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 39th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $72 | 2 | |
| 2022 | General | $21 | 1 | |
| 2021 | General | $61 | 3 | |
| 2020 | General | $230 | 12 | |
| 2019 | General | $825 | 48 |
Beside peers
- Maged Hosny
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Maged Hosny were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Maged Hosny | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $825 | $744 | $153–$2,687 | $163 |
| 2020 | $230 | $462 | $98–$2,027 | $114 |
| 2021 | $61 | $531 | $101–$2,153 | $132 |
| 2022 | $21 | $627 | $125–$2,303 | $149 |
| 2023 | $72 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 63 drugsPart D claims
8,616
Drug cost
$5,073,267
Branded share of claims
18%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 171 | $1,372,858 | |
| Enbrel Sureclick Etanercept | Brand | 97 | $857,757 | |
| Enbrel Etanercept | Brand | 38 | $410,725 | |
| Cosentyx Sensoready (2 Pens) Secukinumab | Brand | 27 | $318,052 | |
| Orencia Clickject Abatacept | Brand | 41 | $308,125 | |
| Cimzia (2 Pack) Certolizumab Pegol | Brand | 17 | $283,655 | |
| Rinvoq Upadacitinib | Brand | 32 | $218,373 | |
| Humira Pen Adalimumab | Brand | 30 | $204,083 | |
| Humira(Cf) Adalimumab | Brand | 16 | $154,215 | |
| Simponi Golimumab | Brand | 19 | $147,800 |
The 10 drugs with the highest cost, of 63 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 47 billing codesPaid by Medicare
$4,823,794
Medicare patients
1,593
Services billed
442,642
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 39% | |
| Diabetes | 33% | |
| Depression | 27% | |
| Ischemic heart disease | 26% | |
| Chronic kidney disease | 26% | |
| COPD | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 91 | 53,725 | $1,758,564 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 | Office | 58 | 208,800 | $740,822 |
| Injection, denosumab, 1 mg J0897 | Office | 327 | 33,000 | $664,749 |
| Injection, tocilizumab, 1 mg J3262 | Office | 12 | 74,880 | $351,981 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 33 | 29,700 | $259,498 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 19 | 5,420 | $133,910 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 | Office | 25 | 5,760 | $132,774 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 28 | 2,864 | $19,687 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 25 | 125 | $597 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 69 | 5,741 | $590 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
66 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Delaware
Related records
Rheumatology in Delaware
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Delaware
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.